Risk-On & Risk-Off Trades Get Hit… And Insmed CEO On Stock Surge 11/3/25

4 Nov 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Episode Summary: CNBC's "Fast Money" - Risk-On & Risk-Off Trades Get Hit

Episode Overview Host: Melissa Lee Air Date: November 3, 2025 Description: This episode discusses the simultaneous downturn in both risk-on (crypto) and risk-off (defensive staples) trading sectors, exploring their implications for market positioning as we approach the end of the year. Additionally, the CEO of Insmed discusses the company's stock surge and the rollout of their chronic lung disease drug.

---

Key Themes

  1. Market Dynamics: Risk-On vs. Risk-Off
  2. Current State:
  3. Both the risk-on crypto market (e.g., Bitcoin, Ethereum) and the risk-off defensive staples sector (e.g., Kimberly-Clark, Altria) are facing significant declines.
  4. The S&P 500 reflects an overall positive sentiment, but underlying market breadth reveals a different story, indicating potential weakness.
  • Market Sentiment:
  • The VIX volatility index indicates rising market concern, trading around 19 despite a relatively calm market day.
  • The weakening bond market might contribute to this cautious sentiment.
  1. Cryptocurrencies Under Pressure
  2. Bitcoin Trends:
  3. Bitcoin nearing the $105,000 mark but facing recent pressures.
  4. Cryptos like Ether and Solana have seen notable losses.
  5. The discussion highlights the speculative nature of crypto investments and the risks associated with rising interest rates.
  • Investor Strategies:
  • Traders suggest that the best strategy is one that remains aligned with overall market conditions, with a focus on the Fed's signals regarding interest rates.
  1. Insmed’s Market Performance
  2. Company Highlights:
  3. Insmed has seen its stock nearly triple in value due to positive earnings and the rollout of its chronic lung disease drug, Brinsupri.
  4. The CEO emphasizes strong initial prescription rates and potential future catalysts.
  • Future Outlook:
  • Key upcoming events, including the implementation of clinical trials and new indications for their drugs, could further enhance Insmed’s position in the market.
  1. Broader Economic Indicators
  2. Telecom and Staples Sector Weakness:
  3. Telecom stocks such as T-Mobile, AT&T, and Verizon have experienced significant declines amid competitive pressures and changing consumer preferences.
  4. Defensive staples have not performed as expected, leading analysts to reassess their viability.
  • Earnings Season Insights:
  • Mixed results during earnings season point to a narrowing breadth in the market, suggesting caution among investors.

---

Insights & Analysis

  • Market Positioning:
  • The episode encourages traders to consider the broader economic signals rather than focusing solely on the performance of the MAG-7 tech stocks.
  • There is an indication of a potential shift in investment strategies as market conditions evolve.
  • Investor Sentiment:
  • Current bullish sentiment among investors may serve as a contrary indicator, potentially leading to short-term pullbacks.
  • Long-term outlook remains cautiously optimistic, especially with regard to AI-driven sectors.
  • Strategic Recommendations:
  • Investors are advised to carefully evaluate the risks associated with rising interest rates and their impact on both high-growth tech and defensive sectors.

---

Conclusion As "Fast Money" navigates through the complexities of the current market landscape, the discussions highlight the interconnectedness of crypto and staples, the importance of strategic positioning, and the potential for growth in innovative biotech companies like Insmed. The episode serves as a reminder to investors to stay informed and adaptable in a rapidly changing economic environment.

For more updates, follow "Fast Money" on CNBC at 5 PM ET on weekdays.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq market site in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. A market puzzle. One big risk on trade and a big risk on one moving in the same direction over the past week. What it says about the state of the market, how to position it to year end and housing headaches. Homebuilder stocks trading at three month lows. Is there hope for a rebound? We'll talk to the CEO of mortgage lender Better.com for a pulse check. Plus Palantir's post earnings volatility, heavy static for telecom stocks and a biotech company well outperforming the MAG7 this year.

0:34We'll talk to the CEO of Inzmet, fresh off earnings and new approvals for gene therapy drugs. I'm Melissa Lecomte-Lar from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Steve Grasso, Dan Nathan, and Guy Adami. We kick things off November specifically with that trade that made us go hmm. Things that make you go hmm. That's right. The market that makes you go hmm. Both the risk on crypto trade and defensive staples under pressure in recent days. is Bitcoin closing in on the$105 ,000 mark, while the XLP Staples ETF is trading at more than 50 two-week lows. It's not just Bitcoin hitting a wall.

1:06Ether and Solana have both posted double digit losses over the last month in crypto-focused names like Circle, eToro, Strategy, Bullish. They're also struggling. While Kimberly Clark was largely responsible for the Staples move lower today over the past week, we have seen big losses in names from Altria, Hershey to Hormel and Cisco. Staples, also the only S &P sector down year to date. So if both the risk on trade and the safety trades are moving in the same direction, what does that tell us about the state of the market that we're in, Guy? It's a great question, Melissa Lee, and I will attempt to answer it.

1:40I don't think it's, I think it actually is telling the real story. I think the S &P 500 is telling one story. But you look and I'll add a couple other things. At one point today, the VIX traded almost 19 on what was a pretty benign day. You mentioned Bitcoin underperforming. Maybe part of that is Jerome Powell walking back a December cut. But this was in process long before he started talking. You mentioned the staples as well. I mean, there's something clearly going on. And I think the volatility index is sniffing it out. I also think this weakness in the bond market, I want to be careful here, is something that's going to sort of permeate over the next couple of weeks.

2:14So despite the fact that those seven to ten names we talk about are doing very well, market breadth and other things suggest something otherwise. Yeah, market breadth has been miserable. If you're a MAG-7 ETF or a MAG-7 player, life's good. And today was that kind of a day. It has been pointed out. I mean, the equal-weighted S &P is down 6.5 % since September 1st. Meanwhile, semiconductors have outperformed the S &P by 22 % since September 1st. So it just tells you, I mean, a micron, which is doubled. It just gives you some sense of what's going on here. Obviously, we're going to talk about this other headline today, which is Amazon OpenAI, yet another one.

2:50But I think the dollar creeping above 100 on the dollar index is another one of these things. It's not that the dollar, which often can be seen, a dollar rally is a risk off moment. It's just it's a combination of a lot of things. I think the weak dollar trade is something that a lot of people were expecting. I think there's a dynamic that people believe is important for the stock market. And so, yeah, I mean, there's a lot of anecdotal evidence in a world where we apparently don't have real government data anymore that certain parts of the economy. Listen to the shippers. Listen to a lot of different parts of the economy.

3:20Rails over the last couple of weeks have given us actually a lot of data points in terms of what is the most economically sensitive, arguably part of the economy, at least to impact stocks. So I would just jump in and say I think after a heroic run in equities, it's not a surprise to run into some heaviness. I still think this is the best month of the year. I still think we're going to be higher than where we are today by Thanksgiving. Gobble, gobble, guy. And I think it's a case where, you know, you can't overthink this. The Fed's out there. Different members of the Fed are saying we're now more focused on inflation than the jobs market.

3:51And so there's not this green light for straightforward Fed and everything else, even though, again, the most exciting trade in the world is game on. So I think if you wanted to buy the market off this dip, you would have to have a green light by the Fed. So I think that's the number one thing to cut again, to cut again. Number two, Guy said it's been going on for quite some time. The week is a Bitcoin meme stocks, quantum stocks. Those have been bought. Those are the risk ones. Those are the non-profitable companies. And then Jerome Powell last week takes December off the table. That means rates are going higher.

4:25Or the market's saying that rates are going higher. So what goes lower? Staples. It's competitive. Higher rates, they underperform. What doesn't perform well with higher rates is Bitcoin, too. So there's a double reason why Bitcoin doesn't perform well. There were choices a month ago with quantum. Now they have higher rates to look forward to. Yeah, just saying the earnings front, you know, the dollar that Tim just mentioned is kind of doing this rounding bottom. It's back up to that$100 level. And then if you think about rates, if they're not like definitely priced to go much lower from a U.S.

4:58multinational standpoint, there's some pressure there as far as earnings have been a tailwind. And on the crypto thing, I mean, listen, you know, Bitcoin was moving higher when rates were higher, you know. And I think this is one of those ones where you want to kind of say there's certain relationships that make some sense. This thing has defied a lot of relationships. And I think what's going on right now is that over the last couple of years, we had this move. We had ETFs that were being listed. Then we had deregulation. And then we had these treasury strategies. Well, it doesn't seem like there's too many other companies now signing up for these treasury strategies.

5:26And if you think about it, MicroStrategy was first to it. I think they own 640 ,000 Bitcoins. I mean, like 3 % of all the available Bitcoins. That might work out great for Michael Saylor and strategy. It might not work out that well for all these other companies. He is he just owns Bitcoin. The other ones are basically replacing stuff on their balance sheet with Bitcoin. It might end up not doing the thing that they hoped it to do. And then if we ever have a reason for this to unwind a bit, it's going to be quite nasty. And then if you think about you just mentioned all those companies that have gone public who are these trading companies or brokerage firms or whatever.

6:02I mean, if you don't have stable coins, if you don't have a healthy stable coin market, then those companies, I don't know why they exist, right? We already have places in which to trade them. If you look at Robinhood, how much that they trade these things, why do you need a company just designated to be there to trade crypto? Like, that's my personal view. I mean, I have a Robinhood account or a Fidelity account. I can trade it all right there, right? And I can have my 401k there. I don't think that's the thing that those other exchanges are there to do. They're there to kind of do stable coins.

6:30And to me, it seems like a solution in search of a problem. And then when you see technicals on Bitcoin, every time you trade down$5 ,000 worth, you see this delevering come in or risk adjustment come in. To Dan's point, the higher Bitcoin goes, the higher those Robinhood coin stocks will go. But once you take the steam out of it, that unravels to a lot of tentacles in that whole space dramatically quickly. Yeah, I mean, I think that it's a good point that there's a lot more leverage in this trade than there had been before. And so this unraveling happens at a much faster pace. Let's put a pin in it for now.

7:06We've got some breaking news we want to get to on Starbucks. And it's China business. Kate Rogers got the details. Kate. Hi, Melissa. That's right. We've been anticipating this news. Starbucks announcing it's found a partner in China entering into a joint venture agreement with Vuyo Capital. It's a leading alt investment firm to operate Starbucks retail business in China. Now, under this agreement, Boyu will hold up to a 60 percent interest in Starbucks retail operations in China. Starbucks will retain a 40 percent interest in the joint venture, and it will continue to own and license the Starbucks brand and IP to the new entity.

7:39Boyu is going to acquire its interest based on a cash-free, debt-free enterprise value of approximately$4 billion. And Starbucks expects the total value of its China retail business to exceed$13 billion. And two other details here. The joint venture, according to this press release, Starbucks expects this to be finalized in Q2 of its fiscal year 2026 after completing required regulatory approvals. And just a reminder, the China business, Melissa, has really been turning around in the most recent earnings report last week. Same store sales were up 2 percent, boosted by a 9 percent climb in traffic.

8:15And a reminder for viewers, China is extremely important to the Starbucks business. They often refer to it as their second home market. You can see the stock is higher by 2 percent right now on this news. Back over to you. Kate, I'm not familiar with Boyu Capital. Where is it based? So I'm not sure where Boyu is based, but the operations are going to be headquartered in Shanghai, Melissa. I'm still going through the release and I'll bring any updates that are pertinent back over to viewers. OK, thank you, Kate. Kate Rogers on Starbucks. Starbucks shares are up about 2 percent on the announcement of this JV.

8:44Tim, as a shareholder, what do you make of this? Well, on some level, it may be positive you've been concerned about them not being able to do it in China without a partner. There's been a lot of local competition. This Boyu deal, whatever we're calling this deal, where they've given up majority control, is something that this isn't a I mean, there's a headline that's been out there for the last week. And some of this started to come out on their earnings call, which wasn't fantastic. In other words, we get back to the story, which is it's going to be really hard to find what the next catalyst to take Starbucks higher, even though I think you've priced in a lot of bad news.

9:14I don't think you have to run out and buy it. And I don't think this this headline is something that should have people overly concerned about. China is no longer a growth spot. We are learning that Boyu Capital is a Hong Kong based firm. And that may play into the strategy here. You want some Chinese partner. Right. A Chinese partner to be in China. I'll just say this. October 8th, I think it traded down to 80 bucks. Starbucks go back to May traded down to 80 bucks. So if you want to trade against something, it's the 80 dollar level. Obviously, you're through earnings now, so that is a catalyst.

9:46So I actually think you might actually get some momentum to the upside here in Starbucks. You know, it's interesting. Another U.S. brand that's having a tough time over there is Tesla. And you see that some of the local operators are doing much better than Tesla. Tesla is expected possibly to have a 5 % year-over-year decline in China when some of their competitors, X-Pen, NIO, BYD, they're growing at like mid-teens or something like that. So to me, it's kind of interesting. I don't know how a Tesla partners locally. I mean, there isn't a major price war. But it's interesting to think about we're in the middle of this trade war and make no mistake about it.

10:17We're still in it. Some U.S. brands are going to continue to have a hard time for nationalistic reasons, but also operational reasons. Brian Nichols, an operator and you can't count him out. But this is a very hard thing for him to turn around. Right. The amount the sheer amount of stores that you have. He's got a bunch of different levers that he's trying to pull. None of them have worked so far. But technically, this is where the stock should bounce. This has been support going back to April. I would take a flyer out on it. All right. Meantime, Evercore ISI finding unprecedented bullishness among clients in its latest weekly market sentiment survey.

10:48Let's bring in Julian Emanuel, the firm's senior managing director. Julian, great to have you with us. Great to be here. So you were shocked by these results. Shocked. So, look, and again, part of it is a function of the fact that contrary to a lot of people's expectations, ours included, September and October were as strong as they were. And frankly, we all know what the calendar looks like, that November and December tend to be positive months anyway. But this level of bullishness in our mind is a bit of a contrary indicator. Going back to 2018, the second highest reading we got when we asked what's the next 10 percent in the S &P 500 was 69 percent set up.

11:27Last week, it was 76 percent. And, frankly, when you think about the setup and you think about last week, we got a lot of good earnings news. We got a lot of good geopolitical news. And the market just really sort of didn't go anywhere at the index level. And we've got a little bit of an information vacuum the next couple weeks and a government that's still shut down. So it's a near-term cautious setup, in our view. But longer term, you are bullish. Absolutely. Absolutely. You know, as uncomfortable as owning stocks at this valuation has been, and frankly, we want to see it become uncomfortable once again.

12:10You know, you look at the AI story, it continues to get better. And the earnings are just incredible. So what you're saying is basically disregard some sentiment and stay in for the long haul if you're that type of an investor. But to the extent that we just got done talking about market breadth, which is narrowed almost to, you know, a short little kind of triangle here. What does this mean? Is this part of your euphoria dynamic or would you be concerned more broadly about market breadth? We all know there's a headline tomorrow. There's another one next week and there's another one next week.

12:46That's about retrofitting AI capacity and all these big boys that are already there. We know those headlines are coming. The rest of the market's not doing much. Right. Well, so and if you look at this last couple of years of bull market, unlike the late 1990s, which we are all fond of comparing it to, you've had market breadth expand the entire time, whereas in the late 90s it was declining for those last couple of years. And so to sort of lose that prop the last few weeks is certainly a worry. And to your point earlier, Tim, is nobody is positioned for a stronger dollar. And when that's the case, you tend to have other pain trades.

13:26Bitcoin is certainly likely to be one of those. And the entire recipe tends to be something that will likely spread the caution. Again, we're not going to have any more information until the last of the MAG-7 reports two weeks from now. How problem, by the way, I don't think this is going to happen. I think they cut in December. But how problematic for the market would be if they didn't cut in December? It would be pretty problematic. In our view, they are going to cut. We still, basically, if you look at the market implied probability, it's around 65 percent today. We think actually, counterintuitively, we'd rather see that move down to 50 percent because that's when you put a little starch into the VIX and you put a little fear in people's eyes and you get your buying opportunity.

14:16Julian, how concerned are you over the SCOTUS decision on tariffs right now? And if they rule against tariffs, does that just make you more bullish because the cuts would probably be coming? Well, here's the problem, Steve. Do we as investors actually like tariffs now or do we not like them? The market likes them. The market does like them. And our concern is probably less than an adverse ruling because our policy people think the Trump administration will be able to find a workaround to call it 80 to 90 percent of the tariffs that are on the books right now. And more whether the payback is mandated, the 250 to 300 billion dollars that's been collected.

14:59it. That's the kind of jolt that the interest rate market is not prepared for. Interest rate volatility is actually lower than equity volatility right now. Going back, though, to the contrarian indicator of your survey, in the short term, do you think that indicates the bullishness, the extreme bullishness that you've seen, a short-term pullback? And if so, what magnitude of a pullback? We don't think, again, given the seasonality of November and December, it's going to be all that incredible. You know, the 50-day moving average, which is about 3 % below where we are right now, has held most of the pullbacks the last several months.

15:41But frankly, when the market is priced at 26 times and there is an element of complacency against all assets, it's probably enough, again, to create a more robust buying opportunity. Julian, great to see you. Thank you. Thank you. Julian Emanuel. I love the expression, put starch in the volatility. Yeah, I mean, it's very... You must get a visual on that. Right, right. You can just feel it stiffening up. Absolutely. But would you agree with the assessment in terms of where we are right now, Dan? Yeah, I mean, there seems to be a bubble in calling a bubble in AI. And that's something, no, I mean, and I get it.

16:19I look at the market and I see these two things, right? Tim just kind of described what's going under the hood and the RSP, the equal weight versus the mega cap weight. And I hear a lot of folks talking about how the financials have participated, industrials have joined the party, that sort of thing. And I say to myself, there's no way this market is going to come down meaningful if it's not done by this AI sort of trade. Like, that's it. And look what's going on in the aftermarket right now. I mean, Palantir, I know we're going to talk about it, but this is important to this market conversation.

16:46I mean, stocks unchanged and the guidance that they gave was fine. You know, this is a company that trades 100 times sales. And normally you would say, well, it's not good enough. You know what I mean? People would take in profits and they're not. The other thing as far as the options market is concerned, if you look at any of these sorts of names, the calls are more expensive than the puts. People are more interested in getting upside exposure than they are downside exposure. And that's telling me a lot about something about the psychology with the market right here. Well, speaking of the AI trade, let's get to Amazon here.

17:14surging 4 % today, closing at another all-time high. The latest jump coming after Amazon Web Services and OpenAI announced a$38 billion multi-year cloud deal. Today's move, combined with Friday's post-earnings reaction, marks its best two-day gain for Amazon stock in nearly three years. I read an interesting comment from RBC about this, saying that Amazon, AWS, is the only one with no agreement with OpenAI. And so that was negative investor sentiment surrounding the stock. And now it has an agreement, so it's joined the club. It's A-OK to get in on this trade, Guy. It also did something. So it traded two times normal volume today.

17:49It opened basically where it closed. And you have two gaps lower in the chart. You're setting up for, dare I say, a bit of an island reversal if we open lower tomorrow. I didn't think the news today was that earth shattering. I will say collectively we had been bullish on Amazon into earnings. I think this move today extends it. I think it trades lower from here. I think it validates, though, investments AWS has made. and they're going to retrofit again AI and data center. The capacity on this deal that essentially goes to work right away runs out at the end of 26. So this isn't one of those ones where we're talking about 28 to 32.

18:24This is one that actually really is in play now for a company that has been making the investment. So for a company that I know this is hard to ever say about Amazon, but that has a relative valuation argument in favor of it over at least some of the players and certainly relative to itself, I'm not surprised to see the distraction. Guy's right on the – fascinating on the charts. And to the extent that people were waiting for this kind of an announcement, let's see how much you follow through. But those numbers that they had late last week were great. This just keeps the momentum going out of earnings.

18:54When you see AWS recapture some momentum up 20 % year over year, this is what they had to do because now they have a seat at the table too. I'd be a buyer right here of it. It's a catch-up trade. Yeah, and, you know, OpenAI is interesting. They seem to be – and maybe this is a great strategy for them, I'm more interested in renting this sort of compute than actually building it out. I know Stargate exists, and this is something that's going to come in the future. And, you know, we've got the Oracle deal. We've got all this sort of stuff. But they're spraying this all around. And, you know, you use the word tentacles.

19:20I mean, at some point, if there is – No, it's just the metaphors are flying tonight. Starch. We've got the spray. My only point is – There's a lot of places to go with this. I won't. I mean, things better go right with OpenAI. Because if it's not, the tech sector as we know it is just going to be decimated. Coming up, we're just going to move on. But earnings season rages on. Shares of Palantir on the move after reporting in the last hour. The numbers and details from the latest quarter next, plus a media meltdown, why Wall Street is changing the channel on shares of Comcast. And whether there's any chance of a rebound for the stock.

19:52Don't go anywhere. Fast Money is back in two.

20:04We've got an earnings alert on Palantir. share is volatile even after the company raised its fourth quarter revenue guidance above Wall Street expectations. It also beat top and bottom line estimates. The stock closed the regular session at a record. The conference call kicked off at the top of the hour. CNBC's Morgan Brennan has got more in the quarter. Hey, Morgan. Hey, Melissa. Well, the big earnings takeaway here for Palantir, and this is from the call, is AI is driving the growth. U.S. is driving the AI adoption. Palantir's U.S. revenue grew 77 percent last quarter. U.S. commercial up 121 percent.

20:33Q4 U.S. commercial forecast. It's implied to be similarly strong here. Rule of 40 score. This is an eye-popping 114%. This is an enterprise software metric. Higher is better. I spoke with CEO Alex Karp, and I asked whether he thinks an AI bubble is inflating and or a shakeout coming across the tech space more broadly, given all the deals being struck, all the capital pouring in. He told me, quote, here's this large set of the AI market that works, either in consumer or enterprise. The things that are valuable will remain valuable. The things that are not valuable are going to get flushed out. The strong companies are going to get much stronger.

21:07And the people pretending they're doing stuff are going to disappear quickly. And I think looking at Palantir's numbers, he would be suggesting that Palantir is one of those valuable companies that gets more valuable. The conference call is still ongoing. The last thing I would say, Melissa, on this, and this was a big part of my call with CARP, conversation with CARP, And it's a big part of this conference call right now is what this new AI era and implementation of it is going to do to the economy and to the workforce. CARP talking about a worker available GDP and that that's the focus of Palantir.

21:38But basically saying that what's going to be valued within the workforce and what that's going to mean in terms of demographic breakdown and how that's going to reverse and change is underway here. And it's going to that AI is basically going to change what we consider the most important when it comes to workers of the future. Morgan, thank you. Fascinating stuff. Morgan Brennan on Palantir. We should know in terms of the reaction, the stock sort of in the after our session at this point, it had beat 19 out of the past 20 quarters and about half the time traded up, half the time traded lower. So you never know.

Read the full transcript

22:12It's a coin toss when it comes to the reaction to the actual earnings. Dr. Karp said it was the best quarter of software companies ever. I'm not going to argue with him. Okay, that's fine. And it's probably true. The margins were spectacular. Numbers are great. Here's the problem. Dan points this out. I will point it out as well. It trades north of 90 times revenue, which historically we have never seen before. Now, if you say, you know what, G-Swids, they're going to grow into that, that's fine. They've got to grow really quickly in order to get to that valuation. And I don't think we're anywhere close.

22:40I mean, they'll do maybe$6 billion of revenue sitting on top of a half a trillion dollar company. It trades above, to Guy's point, above 100 times EV to sales. 55 % of it is from the U.S. government. 66 % of revenues are domestic revenues. But when you think about it, they're in the crosshairs. The Trump administration is friendly with them. Did they take a stake in them yet? They didn't, right? They're talking about taking a stake. Well, the venture arm of the CIA has a stake, and they're one of the original backers. But did the Trump administration, akin to Intel, Did they take a 10 % stake?

23:16I don't think they did as of yet. Why would they? So you're saying it should be a strategic? Because they've been talking about it. It's a strategic asset. It's a defense. You look at anything in cyber, buy high, sell higher? So are you saying despite the valuation, there could be a government stake? That's the only reason. I could have bet against this company a while ago. I didn't want to buy a company that was 55 % dependent on the U.S. government. But you do have a friendly government for the next couple of years. So you might not be wrong in buying it now. I just feel the government story is well known in the stock.

23:52I almost feel like the stock trades as if it has a strategic partner in the government. And effectively, they do. And we know that government, the government component of the growth means 52 percent of revenues. And it continues to kind of be sizable. I mean, that's good and bad. And I understand that with this administration, it's been fantastic. You know, I wouldn't bet a bet against this company in the current environment we have. I think everyone's right to point out that the valuation makes zero sense. The valuation has not made sense for three years in Palantir, and it goes higher. Yeah, except that a year ago it was trading at$40.

24:23Right now it's trading at$208, right? And that obviously, you know, that's that difference between$50 billion and$450 billion or whatever it is. But, like, to guys, we've just never seen a stock like this, not at this scale. And, you know, it's a software company, okay? And it takes sales, and it takes people to implement it, and it takes people to kind of update stuff. And, you know, all of this revenue that they're speaking of,$4.4 billion this year, it's not all AI related, too. So I just think that no one's really drilling in and doing a whole heck of a lot of work. There's momentum stocks.

24:52It's a great story. It continues to work. At some point, it's not going to be able to grow into this valuation. All right. Palantir shares flat right now in the aftermarket. Coming up, Palantir may be surging this year, but there is a lesser known biotech keeping pace. What is driving InSmit stock and what the CEO sees in store for the company? You're watching Fast Money Live from the Nasdaq Market site in Times Square. Back right after this. Look, look, everybody.

25:26Welcome back to Fast Money. Comcast shares down 3 % today, closing at levels not seen in more than nine years. The latest move coming is a slew of analysts cut the price targets on the stock. Citi, Goldman Sachs, Deutsche Bank, Barclays, all lowering estimates after Comcast last week reported a fourth consecutive quarter of broadband subscriber declines. Comcast owns NBCUniversal, which is currently the parent company of CNBC. So logically, we do watch Comcast shares very closely. And it's been a really rough ride for this one. What do you think of this? Nine-year low. You just said I think it was January of 16.

26:00This is a huge support level because you get through here and there is open water probably down to a teenager. When I say teenager, 18 and a half, 19. Now, people are going to point to valuation and say it's cheap. Problem, of course, is that's been as expensive as Palantir has been on the way up. That's how that's how cheap Comcast has been on the way down. You don't buy this for valuation. Yeah. One of the unfortunate things like so. I know we've been talking a little bit about this YouTube TV and this Disney thing. Right. So I have YouTube TV and I don't get to watch ESPN. You know what I do?

26:30I canceled that. I got Hulu. Like the idea that you would ever go back to a proper cable situation. It just doesn't exist anymore. So, again, it's sadly a melting ice cube, that business. And we'll see, because it really is YouTube TVs and the streamers game to win here. Right. At 10 straight quarters of contraction and you lost another hundred and something thousand in broadband subscribers, which is the largest part of the business. And again, when that starts to shrink, it's really a concern. I think more indicative of just what's going on overall in what we're seeing in telco, what we're seeing in cellular.

27:05It's been a rough month. Coming up, a biotech boom. Shares of InSmet have more than doubled since the summer. What is pushing the stock higher and what the CEO says will drive results going forward? He'll join us next when Fast Money returns.

27:26Welcome back to Fast Money Stocks Mix to kick off November. The Dow falling more than 200 points. The S &P up about two-tenths of a percent. And the Nasdaq climbing about a half a percent. Kimberly-Clark announcing a deal worth nearly$49 billion to acquire Tylenol maker Kenview. The move coming just weeks after the Trump administration made unfounded claims linking Tylenol use during pregnancy with autism. Kenview shares up 12 percent today, while Kimberly-Clark dropping nearly 15 percent on the news. Jim Cramer, by the way, will be speaking exclusively with Kimberly-Clark's chairman and CEO on Mad Money tonight.

27:57That's 6 p.m. Eastern time. Shares of Eli Lilly getting a boost of nearly 4%. The pharma giant planning to build a$3 billion plant in the Netherlands to expand production capacity for its weight loss pill. Lilly in September announced a$6.5 billion plant in Houston, Texas. And Serefto Therapeutics plunging after hours. The company saying its Duchenne muscular dystrophy treatment did not show significant improvement versus a placebo in the latest study. It also posted a drop in revenues for the latest quarter and swung to a net loss. Those shares down just about 36%. Even with a slight pullback today, InsMed up over 11 % since reporting earnings just last Thursday.

28:34The rare disease drugmaker posting strong sales of its lung disease treatments, including Brinsupri, a first-in-class drug that launched during the quarter. So far this year, InsMed shares have kept pace with one of the market's high flyers, Palantir. Prior to the software's company's earnings tonight, both stocks are up roughly 170 % year-to-date. Joining us on set for more, InsMed CEO Will Lewis. Will, great to have you with us. Guy was remarking that the first time you were on the show, the stock was, what,$30? Yeah, that's right. So this has been quite a journey that you've been on. During this past quarter, we had the launch of Brinsupri, which had been better than what analysts had been expected.

29:07Q4, though, should be the test. So can you sort of walk us through the push and pulls going into Q4? There was some indication on the calls, I understand, that there could be a more normalized run right in Q4. But there are a lot of other positive catalysts that could also come about in Q4, like improvement in back office, improvement in payers, et cetera. So there's a whole lot of reasons for us to be excited at the moment at the company. The first is that the Bren Supri launch in its early days, and it's only six weeks of data, looks very, very strong. We had good breadth of prescribing. We had as many as 2 ,500 patients on drug, which is fantastic out of the gate.

29:44Q4 is the first full quarter, and so we really need to see that to know what the shape of the launch curve is going to be. But we're certainly optimistic about that. And behind that, we have a whole host of other clinical and commercial catalysts that we think are going to continue to drive value at the stock. If you were to make the case that there could be some upside thing, you know, catalysts that happen in the quarter that would lead to continued uptake of Brin Supri, what would those be? You know, there could be inclusion, for instance, in the U.S. recommendation in terms of how this disease is treated, and that could help Brin Supri uptake.

30:16What else is there that investors should consider? So chest guidelines just came out, and they're draft guidelines, but we were included and recommended for use under those guidelines. And that's not surprising. This is the first and only approved therapy for the treatment of bronchiectasis. This is a disease that's been around since 1819. So for 200 years, no one has been able to develop a drug that could have an impact until we came along. So we're very excited about that, take that responsibility very seriously. We have a lot of disease education going on. as far as catalysts that will drive it from here.

30:47It's really the breadth and depth of prescribing. We need the centers of excellence to continue to write scripts for patients that will benefit from the therapy, as well as expanding to the almost 30 ,000 pulmonologists across the United States that are in a position to write this drug. There's a lot of penetration to come in terms of prescriptions. When it comes to your pipeline, though, a lot of analysts are looking forward to Jan 2026 when there's going to be the Birch data phase 2 readout. Can you walk us through what that could mean for expanded use of this compound? Well, if you take a step back and think about where Insumet is, we are currently serving between the addressable markets for our first drug, Eracase, and our second drug, Brinsupri, roughly 250 ,000, 280 ,000 addressable patients at the moment.

31:31Between now and the end of this decade, that could increase to over 2.5 million if these various drugs and pipeline prove to be successful. The first check of that will be in January at the J.P. Morgan Healthcare Conference, where we'll have data on CRS without nasal polyps. As you mentioned, there are more than 30 million people in the U.S. alone that have this condition. There's only one generic steroid approved to treat it. So if we were able to make a dent there on the most severe end of the patient spectrum, that would be a significant advance for the company. Well, congratulations. And people were saying, can they go it alone?

32:02And so I'll ask,$1.7 billion cash, cash equivalents, marketable securities, how long a runway does that give you? Well, we have a lot going on at the company. I like to say that next year, if things fall into place, we could be kicking off almost as many as a dozen phase three trials for multiple indications. So this, as much as we've had a lot change in the last 18 months, the next 18 months are going to be even more eventful. We have a very strong cash position, as you say, and I think that's going to serve us well. As revenue grows from the launch of Brinsupri and Eracase continues to perform, we certainly expect that the clinical spend will pick up as we go after these different indications.

32:40But we have a lot of resource behind that, so we should be in good shape. So of all those phase three, so that indicates that those experimental drugs are closer to market in theory. So what is the next drug that you would expect to be approved? So the next one that's of the first three, we have Eracase, which is looking to expand. We have Brin Supri, which is currently approved for bronchiectasis, and we're awaiting data for CRS without nasal polyps and HS, hydradenitis suprativa, which will come in the first part of next year. And then we have TPIP, which is the drug that we put phase two data out in pulmonary hypertension earlier this year.

33:14That's going to be addressing as many as four different indications, PAH, PHILD, IPF, and PPF, and all four of those programs will kick off next year. Wow. So in terms of all those different indications, the drug has to be approved for each. So are the trials designed individually for each of those indications, or is it simultaneous? Well, they'll all be running in parallel, but each one is designed for each specific indication. And obviously there's some read-through from one to the other that's helpful directionally, but we're in a very good position. Behind all of that, we have another close to 30 preclinical programs that are going to be entering the market over the next several years.

33:51We're targeting one to two INDs a year for the next several years, so this is really just the beginning. Is all this, I mean, is all in-house? I mean, are you acquiring molecules like some other companies are doing from overseas or elsewhere? All of what I've just described is already in-house. We still have a business development effort that's underway, and we're going to continue that in the current environment. There are a number of great technologies and molecules out there. We'd love to add them to our collection. We want to make sure that each drug we bring in, though, is first or best in class.

34:21And if we have that, then we know the impact on the patient will be there. And as we like to say, everything else will take care of itself. Will, great to see you. Thank you so much. Keep us posted on the progress of all these. It's a pleasure. Will Lewis. There's a company we used to talk about years ago, Celgene. I think it was bought in 2019 by Bristol for about$74 billion. That's six years ago. So to me, and Will's still here listening to this, but this is this generation Celgene in a lot of different ways. So despite the fact that the stock has been on a rocket ship, I think it's got a lot more to go.

34:50Coming up, putting the AI in appraisal to see if better.com joins us next to lay out how the company is bringing artificial intelligence to the housing space and why the latest Fed rate cut could unlock thousands of dollars from savings for millions of Americans. And do not miss Treasury Secretary Scott Bessent on Squawk Box tomorrow. That's 8 a.m. Eastern time right here on CNBC. More Fast Money in two.

35:19Welcome back to Fast Money. Mortgage rates are down substantially from where they started in 2025 with a 30-year fix now around 6.5%. Our next guest says that could translate into big savings for millions of homeowners who locked into 7 % or 8 % mortgages. Vishal Garg is the founder and CEO of Better.com, the first AI-powered mortgage lender. Shares of the company are up more than 700 % this year. He joins us now on set. We've got a high bar in terms of letting CEOs on the show tonight to stock performance. Vishal, great to have you with us. Thank you so much. So I have to ask you because I'm sure that intro, everybody's saying, well, what can I do?

35:54I want to save. So what is it in terms of you're in a seven or eight percent mortgage right now? What can you do to unlock savings? If you've got a seven and a half percent mortgage, then that's 20 million Americans have over a seven percent mortgage that they've gotten over the past three years. The best thing you can do is look for a refinance. The average mortgage rate is around six and a half percent. We're at 6.2 on Better.com. And that 80 basis points,$400 ,000 loan balance, you know, you can save 3 ,200 bucks a year in interest. And that's pretty decent money in inflationary times and where, you know, times are tough and we're going into a recession.

36:29Yeah. In terms of how your business works, I mean, I'm assuming that some of these, you know, a 6.2 percent rate versus a 6.25 percent refinance rate, that difference is partly because of the money that you are able to save because you're using AI. That's right. The average mortgage company, it costs them about$12 ,000 to make a mortgage. $3 ,000 to make a mortgage. Our AI loan officer, Betsy, is able to automate so many of the tasks. Betsy's not a person, by the way. I'm just making it to the audience. It sounds like he's talking about somebody in the next office. I mean, as far as he's concerned.

37:04But anyway, sorry to interrupt. I would tell you that Betsy's better than 80 % of the loan officers that you've seen out there. She's trained on 12 million phone calls. She knows all the underwriting criteria across all the investors. She can calculate savings for you. She can figure out what's a better option for you. She can ask you all these questions that people otherwise don't have time for. And she's open for business 24-7, 365. Vishal, congratulations, number one. Number two, people say, well, what's a comp? Figure IPO. Talk about how you stack up against them. Well, I think Figure's a great company.

37:32They're focused on the home equity space. And the average American family can save a lot of money by taking all the debts that they have and refinancing them using a home equity line of credit. Americans are sitting on$32 trillion of tappable home equity. They've got 18 trillion of debts, half of which they put on since the pandemic. And so we're seeing an average family save eleven hundred bucks a month by refinancing through home equity. Figure was the leader in the space. They started in 2018. We launched our home equity product in 2023. We're only about 18 months in, but our direct to consumer home equity product is already two thirds the size of figure.

38:08And we're now catching up fast. They're about five and a half times bigger than we are. But, you know, they trade at like something like eight, nine billion dollar valuation. And so, you know, our valuations just around a billion. So if you think about it from that perspective, we're growing faster than they are. They've done a great job of establishing that there's a bear there in the market and reintroducing the home equity product. But we're growing much, much faster than they are now. So, Vishal, then how about the competitive landscape? And you say you're AI driven, but it just seems to me that the adoption rate in AI is such.

38:39And I would think there are a lot of industries where absolutely AI will be changed the playing field in terms of the efficiencies of the business. Why aren't other people popping up in your space doing the same thing? Well, they are. But how are you leading them? That's a really great question. The average mortgage company works off of eight different systems. They have a CRM system, a point of sale system, a system for the loan officers, a system for the processor system for the underwriters. We built a system called Tin Man from the ground up. It's the first new end-to-end system in the mortgage industry in 25 years.

39:13The incumbent solution that's got 90 % market share, you can't even have more than one person working in the file at any time. You probably remember from your Windows 95 SharePoint days where you had to call somebody up and say, hey, can you get out of the file so I can get back in there? That's how the bulk of the mortgage industry works today. And so when you take a look at that, we've got the only end-to-end system, which we then have been able to train the AI on, being able to do any task inside the system. For other mortgage companies, they've got to get rid of the entire core system, retain their entire workforces to be able to implement AI.

39:47So what are they doing? They're like making an AI appointment scheduler. They're making an AI like document retriever. But that's not real AI. Real AI is when you can take massive amounts of costs out of the system and deliver that back in savings to the consumer. Vishal, great to have you. Hope you'll come back. Thank you so much. Michelle Garg. Coming up, a communication breakdown, why telecom stocks are feeling the pressure and how competition is weighing on this group. More Fast Money in two.

40:25Welcome back to Fast Money. Telecom stocks losing signal today. T-Mobile, AT &T, Verizon, all well in the red. T-Mobile, which hit a record high in March, is down more than 25 % from those levels. Dan pointed out the weakness earlier today on the call. Yeah, I mean, this goes with the staples, too. Staples are making 52-week lows, and we started the show with, let's just bookend the show. Yeah, why not? Go back to Staples. You know, you'd think that, okay, stock market's at all-time highs. These stocks trade the other way. But, you know, we have a VIX that was 18 this morning. You'd think these things are catching a bid.

40:55And it's just, I think it's saying something about there's no cares for, like, the sort of yields that these guys have, the slow growth, that sort of thing. So to me, it's like you want to avoid these deemed defensive stocks right here. Yeah. And the defensive stocks that were also including tobacco stocks. And I mean, at one point this year, we were looking, they were outperforming the S &P. They were outperforming. They were holding serve. In fact, they were outperforming the triple Q's of the Nasdaq. So I think there's a rotation dynamic. I think there's a place like I'm long Altria. They had some tough numbers.

41:24There was we don't need to get into that. The fundamentals aren't as good as I thought that they were going into those numbers. But what's happening for telco, tobacco, other core staple high div payers that were defensive and part of a barbell strategy not working. And I don't think they're going to work. Yeah, freights are going higher. No one's buying a dividend payer. But there's really no high growth name. It used to be T-Mobile. You don't have a T-Mobile in the telecom space anymore. Seems pretty saturated right now. I have a legacy position in telephone. I think it's just one of those things.

41:54I have a certificate hanging on my wall. That's it. That's the only reason I'd use it. Yeah. Framed? No. Just like a... You want to come over? No, it should be framed. You want to do nice, quickly, Guy, because we don't have a lot of time. T-Mobile, the$200 levels where we traded down to in January. This is a big support level. So you want to get long, you get long against$200. Up next, final trades.

42:31Time for the final trade. Let's go around the horn. Tim. That Yankees-Mets argument at the break with Guy almost had me forget that I chose GM as my final trade. Go GM. Steve. Amazon, a seat at the table. Dan. Nice. Lemonade. Did you forget, too? I did. This is an AI-powered insurance company. We talked a little bit about that. They report on the prevision. Wait for that, but that's a good name. Guy, do you remember your final trade? Yes, it would be PSX. It used to be Phillips 66. It's now PSX Corp. Melissa, back to you. All right. Well, thank you for watching Fast Money. Have a wonderful evening.

43:03See you back here tomorrow. Mad Money. June Kramer starts right now.

43:14All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:48To view the full Fast Money disclaimer, please visit CNBC.com forward slash Fast Money disclaimer.

From the publisher

Both the risk-on crypto space and the risk-off defensive staples sector getting hit today. What the dual downer means for the market, and how the Fast Money traders are positioning for November. Plus Shares of Insmed nearly tripling in 2025. What the CEO sees in store for the company as they rollout their chronic lung disease drug.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Risk-On & Risk-Off Trades Get Hit… And Insmed CEO On Stock Surge 11/3/25CNBC's "Fast Money" · 44 min
Listen in VO